Gilead‘s product sales fueled the significant increase in revenue and profit. Its total product sales for the fourth quarter of FY 2014 were $7.2 billion compared to $3 billion for the fourth quarter the year prior.
Driven by sales of hepatitis C drugs Sovaldi and Harvoni, Gilead’s antiviral product sales skyrocketed in the fourth quarter of 2014 to $6.7 billion, up from $2.6 billion for the same period of 2013.
More articles on healthcare finance:
CFO vs. CIO: Bridging the gap in perspective
10 pieces of advice hospital CFOs shared this month
5 CFOs in the headlines this week
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
